Lu Daopei Medical Group
Founded by "Father of Asian BMT" Acad. Lu Daopei · China's #1 Hematology Brand · World's Largest HSCT Provider
Overview
Founded by Academician Lu Daopei, the "Father of Asian Bone Marrow Transplantation," who completed Asia's first BMT in 1964. After 60+ years, the group has become China's largest hematology provider and the world's largest allogeneic HSCT provider.
The group operates an advanced CAR-T immunotherapy platform and 4th-generation nanopore gene sequencing diagnostics, achieving outstanding results in relapsed/refractory leukemia, lymphoma, and myeloma. TONAN Health is its designated cooperation partner.
Key Facts
Acad. Lu Daopei — Father of Asian BMT
Academician of the Chinese Academy of Engineering, professor at Peking University and Fudan University, Vice President of the Asian Hematology Association (AHA). In 1964, he completed Asia's first allogeneic BMT, laying the foundation for China's HSCT field.
Four Affiliated Hospitals
Hebei Yanda Lu Daopei Hospital
Located in Yanjiao, Langfang, Hebei — the group's largest facility. Houses a large-scale HSCT center and comprehensive hematology system, handling the highest volume of transplants and cell therapy.
Beijing Lu Daopei Hospital (Yizhuang)
Located in Beijing E-Town, specializing in 4th-gen nanopore sequencing diagnostics, targeted therapy, and CAR-T immunotherapy clinical translation.
Beijing Lu Daopei Hematology Hospital (Shunyi)
Located in Beijing Shunyi, focused on outpatient hematology, day chemotherapy, post-transplant recovery, and long-term follow-up.
Shanghai Xindaopei Hematology Hospital
Located in Shanghai, serving the Yangtze River Delta and international patients with globally aligned hematology care and cellular immunotherapy.
Core Technology Platforms
Hematopoietic Stem Cell Transplantation
World's largest allogeneic transplant volume, covering all transplant types
Lu Daopei Medical Group performs more allogeneic HSCTs than any institution worldwide. Covering matched sibling, haploidentical, unrelated donor, and cord blood transplants, with particular expertise in challenging haploidentical cases.
Matched Sibling
Classic transplant protocol
Haploidentical
Parents/children can donate
Unrelated Donor
China Marrow Donor Program
Cord Blood
From Hubei Stem Cell Bank
CAR-T Immunotherapy
Breakthrough therapy for relapsed/refractory hematologic cancers
The group has accumulated extensive clinical experience in CAR-T therapy for relapsed/refractory ALL, DLBCL, and multiple myeloma, achieving internationally leading remission rates.
Precision Diagnostics Platform
4th-Gen Nanopore Sequencing · 99.9% Single-Read Accuracy
Equipped with 4th-generation nanopore sequencing technology for precision molecular classification of hematologic cancers. Long reads, real-time analysis, and superior structural variant detection ensure accurate diagnosis.
Hematologic Cancer Typing
Precision molecular diagnosis for leukemia/lymphoma/myeloma
MRD Monitoring
Ultra-high sensitivity minimal residual disease tracking
Targeted Therapy Guidance
Mutation-based matching of targeted therapies
Role in the Ecosystem
Lu Daopei Medical Group is not only a premier hematology brand but also a key pillar of the partnership ecosystem:
TONAN Health Designated Partner
Through the TONAN Health platform, international patients can directly access Lu Daopei's four hospitals and expert teams.
Synergy with Hubei Stem Cell Bank
Also founded by Acad. Lu Daopei, the Stem Cell Bank enables patients to store cord blood or autologous stem cells before transplantation.
Complementary to Lecheng Hospitals
Lecheng hospitals offer cutting-edge stem cell/gene therapies, while Lu Daopei provides the dual-track approach of traditional HSCT + CAR-T.
Interested in Hematology Treatment or HSCT?
Our medical advisors will connect you with the most suitable Lu Daopei hospital and specialist team based on your condition.
Book a Consultation